Are you developing multispecifics? In this short case study about Tarlatamab – a CD3/DLL3-targeted bispecific T cell engager for the treatment of small cell cancer – we illustrate our approach to assess multi-specifics in relevant cell co-cultures.
Key data presented in this BiTE case study:
- Tumor cell line selection & assessment of BiTE specificity
- Co-culture with primary immune cells & measurement of tumor killing in dose-response format
- Characterization of immune response (cytokine release, T cell activation, cytotoxic effector molecules)
Any questions? Our team can customize the tumor cell lines, immune cell populations, and standards to fit your target indication and preclinical development goals.
